Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 20, 2006

Cato to Provide Strategic Drug Development Services for Jenken in Exchange for Equity

  • Jenken Biosciences signed a services agreement valued at up to $2 million with Cato Research, a global CRO, and Cato BioVentures, its venture capital affiliate. Under Cato BioVentures' equity-based compensation model, Cato Research will provide strategic drug development services and regulatory advice related to the clinical development of JKB-122, Jenken's lead drug candidate for the treatment or prevention of liver damage associated with hepatitis C and other diseases associated with organ inflammation.

    "Cato BioVentures and Cato Research are committed to working with early- stage companies like Jenken. When we partner early, as we have here, we can make a positive difference in the overall development of promising drug candidates like Jenken's JKB-122, a compound with exciting potential to impact the treatment of hepatitis C-related inflammatory liver disease," said Shawn K. Singh, managing principal of Cato BioVentures. "This strategic development agreement is flexible, broad-based and reflects a tight fit between our venture program and Jenken's innovative drug repurposing model."



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »